Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Predictive Role of Glutathione-S-transferase Gene Polymorphisms in Risk and Prognosis of Hepatocellular Carcinoma

  • Li, Cheng-Gang (Department of Surgical Oncology, Chinese PLA General Hospital,) ;
  • Zhao, Zhi-Ming (Department of Surgical Oncology, Chinese PLA General Hospital,) ;
  • Hu, Ming-Geng (Department of Surgical Oncology, Chinese PLA General Hospital,) ;
  • Liu, Rong (Department of Surgical Oncology, Chinese PLA General Hospital,)
  • Published : 2012.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Aim: We conducted a prospective study in an Chinese population to detect associations of GSTM, GSTT and GSTP polymorphisms with hepatocellular carcinoma (HCC), and analyze roles in determining survival outcome. Methods: A prospective follow-up study was conducted with 476 HCC patients and 481 controls collected from May 2005 to May 2007. All patients were followed up until the end of Dec. 2011. GSTM1, GSTT1 and GSTP1 genotyping were performed by PCR-CTPP methods. Results: Null GSTM1 carriers had a 1.64 fold risk of HCC compared with non-null genotype, while GSTP1 Val/Val carriers had a 93% increased risk over the GSTP1 IIe/IIe genotype. The median follow-up time for the 476 patients was 34.2 months (range: 1 to 78 months). Individuals with null GSTM1 genotype had better survival of HCC than non-null genotype carriers (HR=0.71, 95%CI=0.45-0.95). Similarly, GSTP1 Val/Val genotypes had significant better survival than the GSTP1 IIe/IIe genotype (HR=0.34, 95%CI=0.18-0.65). Individuals carrying null GSTM1 and GSTP1 Val/Val who received chemotherapy had lower risk of death from HCC than those without chemotherapy. Conclusion: This study indicated carriage of null GSTM1 and GSTP1 Val/Val genotypes to have roles in susceptibility to and survival from HCC.

Keywords

References

  1. Abd El-Moneim E, Younis FA, Allam N, Gameel K, Osman M (2008). Gene deletion of glutathione S-transferase M1 and T1 and risk factors of hepatocellular carcinoma in Egyptian patients. Egypt J Immunol, 15, 125-34.
  2. Ambrosone CB, Sweeney C, Coles BF, et al (2001). Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res, 61, 7130-5.
  3. Asim M, Khan LA, Husain SA, et al (2010). Genetic polymorphism of glutathione S transferases M1 and T1 in Indian patients with hepatocellular carcinoma. Dis Markers, 28, 369-76. https://doi.org/10.1155/2010/328408
  4. Borst L, Buchard A, Rosthoj S, et al (2012). Gene dose effects of GSTM1, GSTT1 and GSTP1 polymorphisms on outcome in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol, 34, 38-42. https://doi.org/10.1097/MPH.0b013e3182346cdd
  5. Boyer TD, Kenney WC (1985). Preparation, characterization and properties of glutathione S-transferases. In: Zakim D, Vessey D, eds. Biochemical pharmacology and toxicology. New York, NY: John Wiley & Sons.
  6. Chen B, Cao L, Zhou Y, et al (2010). Glutathione S-transferase T1 (GSTT1) gene polymorphism and gastric cancer susceptibility: a meta-analysis of epidemiologic studies. Dig Dis Sci, 55, 1831-8. https://doi.org/10.1007/s10620-009-1000-4
  7. Chen YL, Tseng HS, Kuo WH, et al (2010). Glutathione S-Transferase P1 (GSTP1) gene polymorphism increases age-related susceptibility to hepatocellular carcinoma. BMC Med Genet, 11, 46.
  8. Dalhoff K, Buus Jensen K, Enghusen Poulsen H (2005). Cancer and molecular biomarkers of phase 2. Methods Enzymol, 400, 618-27. https://doi.org/10.1016/S0076-6879(05)00035-2
  9. Giera S, Braeuning A, Kohle C, Bursch W, Metzger U, Buchmann A, Schwarz M (2010).Wnt/beta-catenin signaling activates and determines hepatic zonal expression of glutathione S-transferases in mouse liver. Toxicol Sci, 115, 22-33. https://doi.org/10.1093/toxsci/kfq033
  10. Goekkurt E, Hoehn S, Wolschke C, et al (2006). Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br J Cancer, 94, 281-6. https://doi.org/10.1038/sj.bjc.6602891
  11. Han X, Xing Q, Li Y, Sun J, Ji H, Huazheng P, Jun L (2012). Study on the DNA Repair Gene XRCC1 and XRCC3 Polymorphism in Prediction and Prognosis of Hepatocellular Carcinoma Risk.Hepatogastroenterology, 59(119). doi: 10.5754/hge12096.
  12. Hayes JD, Pulford DJ (1995). The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol, 30, 445-600. https://doi.org/10.3109/10409239509083491
  13. Hayes JD, Strange RC (2000). Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology, 61, 154-66. https://doi.org/10.1159/000028396
  14. Hohaus S, Di Ruscio A, Di Febo A, et al (2005). Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res, 11, 2175-9. https://doi.org/10.1158/1078-0432.CCR-04-1250
  15. Kao CC, Chen MK, Kuo WH, et al (2010). Influence of glutathione-S-transferase theta (GSTT1) and micro (GSTM1) gene polymorphisms on the susceptibility of hepatocellular carcinoma in Taiwan. J Surg Oncol, 102, 301-7. https://doi.org/10.1002/jso.21643
  16. Kiran M, Chawla YK, Kaur J (2008). Glutathione-S-transferase and microsomal epoxide hydrolase polymorphism and viral-related hepatocellular carcinoma risk in India. DNA Cell Biol, 27, 687-94. https://doi.org/10.1089/dna.2008.0805
  17. IARC. Globocan 2008: Liver Cancer Incidence and Mortality Worldwide in 2008 Summary. IARC, 2008. http://globocan.iarc.fr/factsheets/cancers/liver.asp.
  18. Mahimkar MB, Samant TA, Kannan S, et al (2011). Polymorphisms in GSTM1 and XPD genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy. Mol Carcinog, Dec 28.
  19. Moy KA, Yuan JM, Chung FL, et al (2009). YuIsothiocyanates, glutathione S-transferase M1 and T1 polymorphisms and gastric cancer risk: a prospective study of men in Shanghai, China. Int J Cancer, 125, 2652-9. https://doi.org/10.1002/ijc.24583
  20. Nguyen TV, Janssen MJ, van Oijen MG, et al (2010). Genetic polymorphisms in GSTA1, GSTP1, GSTT1, and GSTM1 and gastric cancer risk in a Vietnamese population. Oncol Res, 18, 349-55. https://doi.org/10.3727/096504010X12626118080064
  21. Ott K, Lordick F, Becker K, et al (2008). Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. Int J Colorectal Dis, 23, 773-82. https://doi.org/10.1007/s00384-008-0490-4
  22. Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43. https://doi.org/10.1016/S1470-2045(01)00486-7
  23. Pemble S, Schroeder KR, Spencer SR, et al (1994). Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J, 300, 271-6.
  24. Piao JM, Shin MH, Kweon SS, et al (2009). Glutathione-S-transferase (GSTM1, GSTT1) and the risk of gastrointestinal cancer in a Korean population. World J Gastroenterol, 15, 5716-21. https://doi.org/10.3748/wjg.15.5716
  25. Reszka E, Wasowicz W, Gromadzinska J (2006). Genetic polymorphism of xenobiotic metabolising enzymes, diet and cancer susceptibility. Br J Nutr, 96, 609-19.
  26. Roth MJ, Abnet CC, Johnson LL, et al (2004). Polymorphic variation of Cyp1A1 is associated with the risk of gastric cardia cancer: a prospective case cohort study of cytochrome P-450 1A1 and GST enzymes. Cancer Causes Control, 15, 1077-83. https://doi.org/10.1007/s10552-004-2233-3
  27. Saip R, Sen F, Vural B, et al (2011). Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients. J BUON, 16, 241-6.
  28. Shiga H, Heath EI, Rasmussen AA, et al (1995). Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res, 5, 4097-104.
  29. Srivastava SK, Singhal SS, Hu X, et al (1999). Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys, 366, 89-94. https://doi.org/10.1006/abbi.1999.1217
  30. Stoehlmacher J, Park DJ, Zhang W, et al (2002). Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst, 19, 936-42.
  31. Suneetha KJ, Nancy KN, Rajalekshmy KR, et al (2011). Role of glutathione-s-transferase and $CYP1A1^\ast2A$ polymorphisms in the therapy outcome of south Indian acute lymphoblastic leukemia patients. Indian J Med Paediatr Oncol, 32, 25-9. https://doi.org/10.4103/0971-5851.81886
  32. Sweeney C, McClure GY, Fares MY, et al (2000). Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res, 60, 5621-4.
  33. Tahara T, Shibata T, Nakamura M, et al (2011). Effect of genetic polymorphisms related to DNA repair and the xenobiotic pathway on the prognosis and survival of gastric cancer patients. Anticancer Res, 31, 705-10.
  34. Watson MA, Stewart RK, Smith GB, et al (1998). Human glutathione Stransferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis, 19, 275-80. https://doi.org/10.1093/carcin/19.2.275
  35. White DL, Li D, Nurgalieva Z, El-Serag HB (2008). Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am J Epidemiol, 167, 377-89. https://doi.org/10.1093/aje/kwm315
  36. Wideroff L, Vaughan TL, Farin FM, et al (2007). GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Detect Prev, 31, 233-6. https://doi.org/10.1016/j.cdp.2007.03.004
  37. Wiencke JK, Kelsey KT, Lamela RA, et al (1990). Human glutathione Stransferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage. Cancer Res, 50, 1585-90.
  38. Yang G, Shu XO, Ruan ZX, et al (2005). Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer, 103, 52-8. https://doi.org/10.1002/cncr.20729
  39. Zha Y, Cun Y, Zhang Q, Li Y, Tan J (2012). Prognostic value of expression of Kit67, p53, $TopoII{\alpha}$ and GSTP1 for curatively resected advanced gastric cancer patients receiving adjuvant paclitaxel plus capecitabine chemotherapy. Hepatogastroenterology, 59, 1327-32.
  40. Zhang YJ, Chen Y, Ahsan H, Lunn RM, Chen SY, Lee PH, Chen CJ, Santella RM (2005). Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. Cancer Lett, 221, 135-43. https://doi.org/10.1016/j.canlet.2004.08.028

Cited by

  1. Glutathione S-transferase M1 Null Genotype and Hepatocellular Carcinoma Susceptibility in China and India: Evidence from an Updated Meta-analysis vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4851
  2. Independent and Additive Interaction Between Tumor Necrosis Factor β +252 Polymorphisms and Chronic Hepatitis B and C Virus Infection on Risk and Prognosis of Hepatocellular Carcinoma: a Case-Control Study vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10209
  3. Distributions of the GSTM1 and GSTT1 Null Genotypes Worldwide are Characterized by Latitudinal Clines vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.355
  4. Current systemic treatment of hepatocellular carcinoma: A review of the literature vol.7, pp.10, 2015, https://doi.org/10.4254/wjh.v7.i10.1412
  5. Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity vol.11, pp.6, 2016, https://doi.org/10.1371/journal.pone.0157478
  6. Genetic Polymorphisms of Cytochrome P4501A1 (CYP1A1) and Glutathione S-Transferase P1 (GSTP1) and Risk of Hepatocellular Carcinoma Among Chronic Hepatitis C Patients in Egypt vol.54, pp.5, 2016, https://doi.org/10.1007/s10528-016-9749-6
  7. Systemic treatment of hepatocellular carcinoma: Past, present and future vol.9, pp.18, 2017, https://doi.org/10.4254/wjh.v9.i18.797
  8. Association of GST Genetic Polymorphisms with the Susceptibility to Hepatocellular Carcinoma (HCC) in Chinese Population Evaluated by an Updated Systematic Meta-Analysis vol.8, pp.2, 2013, https://doi.org/10.1371/journal.pone.0057043
  9. Glutathione S-Transferase Alpha 4 Prevents Dopamine Neurodegeneration in a Rat Alpha-Synuclein Model of Parkinson’s Disease vol.9, pp.1664-2295, 2018, https://doi.org/10.3389/fneur.2018.00222